Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Clinical and diagnostic substantiation of new approaches in predicting breast cancer in fertile age women

Date

20 Dec 2015

Session

Poster presentation 2

Presenters

Lola Alimkhodjaeva

Citation

Annals of Oncology (2015) 26 (suppl_9): 16-33. 10.1093/annonc/mdv519

Authors

L.T. Alimkhodjaeva, D.A. Nishanov, L.T. Zakirova

Author affiliations

  • Mammology, National Cancer Research Center of Uzbekistan, 100174 - Tashkent/UZ
More

Resources

Abstract 473

Aim/Background

The aim is to study the prognosis of breast cancer in fertile age women with new approaches. Today breast cancer is the most common oncological disease among fertile age women in the world and it is running at 6% of all cancers in this group of women. The very young patients are attended to more unfavorable prognostic features in the tumor: they have more widespread tumors, metastasizing tumors which are characterized by a high-grade tumor and more often with no express of estrogen and progesterone receptors.

Methods

Our study included 130 active fertile age women with breast cancer. All patients were diagnosed the initial stage T1-2 I0 M0. Of these, 17% were women aged 26-30 years, 33% were 31-35 year- old- women, 50% were women at the age of 36-40 years.

Results

According to study results survival at ER(+) and PR(+) was respectively: 97.3%, 94.6%. At negative ER(-) and PR(-) survival rate was respectively 65.4%, 68.7%. When ER positive(+) and negative ER(-), respectively, the survival was 81.5%, 79.3%. At negative ER(-) and positive PR(+), the survival was 90.4%, 88.5%, respectively. In HER2/neu negative patient survival rates were 96.2%, 92.2%, respectively. In group of patients with HER2/neu(2+) expression level these figures were 45.1%, 40.2%. In group of patients with HER2/neu(3+) expression level these rates were 34.3%, 29.4%. When three negative prognosis ER(-), PR(-), HER2/neu-, survival rates were 19.5%, 15.3%, respectively. In the study of tumor morphology 58% of patients were diagnosed with infiltrating ductal carcinoma, 31% of patients were diagnosed with infiltrative lobular carcinoma and 7% of patients were diagnosed with Paget cancer and 4% of patients were revealed rare types of cancer.

Conclusions

Thus, the presence of steroid hormone receptors in breast tumor tissues as well as the absence of oncoprotein HER2/neu correlates with higher 5-year overall and relapse-free survival rates. The absence of steroid hormone receptors, as well as HER2/neu hyper expression in malignant breast tissues, significantly decrease the ratio of 5-year overall and relapse-free survival. The most unfavorable factor for active fertile age patients in terms of prognosis are tumors with ER(-), PR(-), HER2/neu-.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings